OTCPK:NSTM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients’ resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has NovelStem International's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NSTM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.0%

NSTM

0.5%

US Biotechs

1.7%

US Market


1 Year Return

n/a

NSTM

23.3%

US Biotechs

8.5%

US Market

Return vs Industry: Insufficient data to determine how NSTM performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how NSTM performed against the US Market.


Shareholder returns

NSTMIndustryMarket
7 Day3.0%0.5%1.7%
30 Day-1.8%7.7%9.5%
90 Day-32.9%9.0%0.1%
1 Yearn/a24.5%23.3%11.0%8.5%
3 Year-70.1%-89.3%34.3%29.8%32.2%23.5%
5 Year-72.0%-90.0%-3.7%-9.5%58.6%40.8%

Price Volatility Vs. Market

How volatile is NovelStem International's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NovelStem International undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether NovelStem International is trading at an attractive price based on the cash flow it is expected to produce in the future. But as NovelStem International has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is NovelStem International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as NovelStem International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has NovelStem International performed over the past 5 years?

22.7%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, NovelStem International has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is NovelStem International's financial position?


In this section we usually analyse NovelStem International's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. NovelStem International has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of NSTM’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when NovelStem International's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is NovelStem International's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NSTM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NSTM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NSTM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NSTM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NSTM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average board tenure


CEO

NovelStem International has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Mitchell Rubenstein
Co-Founder & Director27.42yrsUS$665.20kno data
David Seltzer
Director1.92yrsno datano data
Jan Loeb
Chairman1.92yrsno datano data
Eric Richman
Director1.92yrsno datano data
Tracy Clifford
Director1.92yrsno datano data
Jerry Wolasky
Director1.92yrsno datano data

1.9yrs

Average Tenure

59yo

Average Age

Experienced Board: NSTM's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

NovelStem International Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NovelStem International Corp.
  • Ticker: NSTM
  • Exchange: OTCPK
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.831m
  • Shares outstanding: 35.38m
  • Website: https://www.novelstem.com

Location

  • NovelStem International Corp.
  • 2255 Glades Road
  • Suite 221A
  • Boca Raton
  • Florida
  • 33431
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NSTMOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 1993

Biography

NovelStem International Corp. focuses on developing and commercialization of diagnostic technology that can predict patients’ resistance to chemotherapy allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. It has a collaboration agreement with NewStem Ltd. for stem-cell technology platform in cancer immunotherapy and COVID-19 resistance. The company was formerly known as Hollywood Media Corp. and changed its name to NovelStem International Corp. in September 2018 as a result of its business focus shift from advertising services to stem cell-based diagnostics for cancer chemotherapies. The company was founded in 1993 and is headquartered in Boca Raton, Florida. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/03 02:19
End of Day Share Price2020/06/02 00:00
Earnings2013/12/31
Annual Earnings2013/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.